StreetInsider.com  Oct 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/CytRx+%28CYTR%29+Begins+Enrollment+in+Aldoxorubicin+%2B+Gemcitabine+Phase+1b/9898587.html for the full story.
newratings.com  Oct 8  Comment 
BASEL (dpa-AFX) - Swiss pharma giant Novartis AG (NVS) confirmed that following completion of the transactions with GlaxoSmithKline (GSK, GSK.L) and Eli Lilly and Co. (LLY) in the coming months, that the three business leaders of the Novartis...
SeekingAlpha  Oct 7  Comment 
By Sharon di Stefano: Targeted cancer therapy is a revolution in drug company research, and Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), recent recipient of a notice of allowance from the US Patent and Trademark Office for a new delivery platform,...
FierceBiotech  Oct 7  Comment 
Closely allied with Eli Lilly, TVM Capital Life Sciences has bumped up its latest fund past the $200 million mark with plans to bankroll up to 15 build-to-buy drug development projects.
newratings.com  Oct 3  Comment 
BASEL (dpa-AFX) - The European Union said Friday that it has approved U.S. drugmaker Eli Lilly and Co.'s (LLY) proposed $5.4 billion acquisition of Swiss drug maker Novartis AG's (NVS) animal health business, as the deal would not raise...
Clusterstock  Oct 2  Comment 
BRUSSELS (Reuters) - EU antitrust regulators will widen a probe into Zimmer Holdings Inc's $13.4 billion bid for Biomet Inc [LVBHAB.UL] but clear Eli Lilly's offer for a Novartis AG unit, three people familiar with the matter said on...
Wall Street Journal  Oct 2  Comment 
Eli Lilly said it would stop development of its tabalumab treatment for lupus, and won't move forward with submissions of the treatment to global regulators.
TheStreet.com  Oct 2  Comment 
NEW YORK (TheStreet) -- Eli Lilly & Co.a ahad coverage initiated ataGuggenheim Securities with an "buy" rating and a $80 price target. Shares of the pharmaceutical company closed up at $65.08 yesterday. Must Read: Warren Buffett's 25 Favorite...
Market Intelligence Center  Oct 1  Comment 
For a hedged play on Eli Lilly and Co (LLY) MarketIntelligenceCenter.com’s patented trade-picking algorithms recommend the Nov. '14 $65.00 covered call for a net debit in the $63.37 area. That is also the break-even stock price for the covered...
SeekingAlpha  Sep 25  Comment 
By Kanak Kanti De: Eli Lilly & Co. (NYSE:LLY) has a robust diabetes portfolio. In the second quarter of 2014, the company's diabetes portfolio generated sales of more than $1 billion. The portfolio was boosted last week after the FDA approved...


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki